News & Updates

Show Multimedia Only

Gout not a risk factor for dementia

17 Mar 2026

Gout does not contribute to an increased risk of overall dementia and may even be protective against Alzheimer's disease (AD) and cognitive impairment, according to the results of a systematic review and meta-analysis.

Gout not a risk factor for dementia

17 Mar 2026

HK study: START-FIT strategy using STRIDE regimen promising in HCC

17 Mar 2026 by

Sequential transarterial chemoembolization, stereotactic body radiotherapy, and immunotherapy (START-FIT) using the STRIDE regimen of single-dose tremelimumab plus regular-interval durvalumab offers promising efficacy and is well tolerated in patients with locally advanced, unresectable hepatocellular carcinoma (HCC), a single-arm, multicentre, phase II study in Hong Kong has shown.

HK study: START-FIT strategy using STRIDE regimen promising in HCC

17 Mar 2026

DTG/3TC tied to lower steatotic liver disease rates in PLWH

17 Mar 2026 by

Switching to dolutegravir/lamivudine (DTG/3TC) was associated with a significantly lower rate of steatotic liver disease (SLD) compared with bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) among people living with HIV (PLWH), according to a subgroup analysis of the PASO DOBLE trial presented at CROI 2026.

DTG/3TC tied to lower steatotic liver disease rates in PLWH

17 Mar 2026

Niacinamide lowers CVD risk in dermatology patients

16 Mar 2026

Supplementation with niacinamide appears protective against some cardiovascular events, such as myocardial infarction and cardiac arrest, suggests a study.

Niacinamide lowers CVD risk in dermatology patients

16 Mar 2026

Pembrolizumab-belzutifan combo improves disease-free survival in clear cell renal cell carcinoma

16 Mar 2026 by

Treatment with pembrolizumab plus belzutifan results in a significant and clinically meaningful improvement in disease-free survival (DFS) compared with pembrolizumab monotherapy in patients with clear cell renal cell carcinoma (ccRCC) who are at greater risk of recurrence following nephrectomy, results from the phase III LITESPARK-022 study have shown.

Pembrolizumab-belzutifan combo improves disease-free survival in clear cell renal cell carcinoma

16 Mar 2026

HF quality of care poorer among Asian vs White patients in US

16 Mar 2026

Quality of care for heart failure (HF) patients varies, with substantial gaps among Asians compared with non-Hispanic Whites, reports a US study.

HF quality of care poorer among Asian vs White patients in US

16 Mar 2026

Novel ingestible gastric balloon holds promise for weight loss

16 Mar 2026 by

A study from Argentina shows the potential of an innovative ingestible gastric balloon, an intragastric device that does not require surgery, anaesthesia, or endoscopy, for weight management in individuals with obesity.

Novel ingestible gastric balloon holds promise for weight loss

16 Mar 2026

No meaningful benefit to adding hormone therapy to PORT in prostate cancer

15 Mar 2026 by

The addition of hormone therapy, either short- or long-term, to postoperative radiotherapy (PORT) offers no survival advantage over PORT alone in prostate cancer, especially for men with very low pre-PORT prostate specific antigen (PSA) levels, according to the POSEIDON study.

No meaningful benefit to adding hormone therapy to PORT in prostate cancer

15 Mar 2026

Maternal smoking ups IBS risk in offspring, but lactation appears protective

15 Mar 2026

Individuals exposed to maternal smoking during infancy show an increased risk of incident irritable bowel syndrome (IBS), while those exposed to lactation display a reduced risk, reveals a study.

Maternal smoking ups IBS risk in offspring, but lactation appears protective

15 Mar 2026

Long-term dupilumab treatment for severe asthma effective in real-world

15 Mar 2026

Patients with severe asthma who receive long-term treatment with dupilumab in real-world settings see sustained improvements in clinical and patient outcomes, with most achieving remission after 2 years, according to interim data of the ProVENT study.

Long-term dupilumab treatment for severe asthma effective in real-world

15 Mar 2026

News & Updates

Showing Multidisciplinary articles

Showing

Specialty:

Gout not a risk factor for dementia

Gout not a risk factor for dementia

HK study: START-FIT strategy using STRIDE regimen promising in HCC

HK study: START-FIT strategy using STRIDE regimen promising in HCC

DTG/3TC tied to lower steatotic liver disease rates in PLWH

DTG/3TC tied to lower steatotic liver disease rates in PLWH

Niacinamide lowers CVD risk in dermatology patients

Niacinamide lowers CVD risk in dermatology patients

Pembrolizumab-belzutifan combo improves disease-free survival in clear cell renal cell carcinoma

Pembrolizumab-belzutifan combo improves disease-free survival in clear cell renal cell carcinoma

HF quality of care poorer among Asian vs White patients in US

HF quality of care poorer among Asian vs White patients in US

Novel ingestible gastric balloon holds promise for weight loss

Novel ingestible gastric balloon holds promise for weight loss

No meaningful benefit to adding hormone therapy to PORT in prostate cancer

No meaningful benefit to adding hormone therapy to PORT in prostate cancer

Maternal smoking ups IBS risk in offspring, but lactation appears protective

Maternal smoking ups IBS risk in offspring, but lactation appears protective

Long-term dupilumab treatment for severe asthma effective in real-world

Long-term dupilumab treatment for severe asthma effective in real-world